AstraZeneca, Bristol partner with Evinova to use AI in drug development
Source: SeekingAlpha
2026-02-18 10:30:44 ET
More on AstraZeneca, Bristol Myers Squibb
- Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
- AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy
- AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
- Bristol Myers wins FDA priority review for multiple myeloma therapy
- RFK Jr. HHS shakeup continues as deputy secretary leaving post - report
Read the full article on Seeking Alpha
For further details see:
AstraZeneca, Bristol partner with Evinova to use AI in drug development
Astellas Pharma Inc. ADR
NASDAQ: ALPMY
ALPMY Trading
-0.75% G/L:
$14.724 Last:
57,125 Volume:
$14.82 Open:
ALPMY Latest News
January 08, 2026 10:30:00 am
VYLOY(TM) (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
December 17, 2025 06:45:00 am
PADCEV(TM) Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 10, 2025 06:30:00 pm
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
ALPMY Stock Data
$29,447,472,947
1,772,218,737
N/A
5
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
